摘要
背景:胃肝样腺癌(HAS)被认为是一种罕见的原发性胃肿瘤,其特征是肝细胞癌样组织学。由于仅根据苏木精和伊红 (H&E) 染色的结果难以检测肝样分化,因此 HAS 经常导致与传统胃腺癌 (CGA) 的诊断混淆。 β-连环蛋白在肝细胞癌(HCC)中高表达,其参与肿瘤起始细胞的维持、耐药、肿瘤进展和转移。由于HAS确诊病例稀少,对β-catenin的研究较少。 目的:选择在我院确诊的14例患者。 方法:对14例患者的临床特征进行统计学研究,并采用免疫组织化学方法对病理标本进行分析。 结果:我们检测到 HAS 癌组织与正常组织之间 β-catenin (P = 0.000)、glypican3 (P = 0.019) 和 hepar-1 (P = 0.007) 的表达存在统计学显着差异。此外,发现HAS癌组织和正常组织中β-catenin的表达之间存在显着相关性(Pearson相关系数:0.686,P = 0.007)。同时,观察到β-catenin的表达与存活时间之间存在显着相关性(Spearman相关系数= - 0.482,P = 0.003)。然而,我们发现 β-catenin 的表达与肿瘤的分化程度和大小、年龄、性别、血清 AFP 水平、微浸润和转移无关(P > 0.05)。 结论:我们的研究结果确立了 β-catenin 作为一个有用的标志物,可以区分 HAS 和 CGA,并可能改善早期诊断,指导 HAS 患者的适当和及时治疗。
关键词: 胃癌、肝样癌、腺癌、β-连环蛋白、甲胎蛋白、肝细胞癌、常规胃腺癌。
Current Molecular Medicine
Title:Aberrant β-catenin Activity in Hepatoid Adenocarcinoma of the Stomach
Volume: 21 Issue: 8
关键词: 胃癌、肝样癌、腺癌、β-连环蛋白、甲胎蛋白、肝细胞癌、常规胃腺癌。
摘要:
Background: Hepatoid adenocarcinoma of the stomach (HAS) has been recognized as a rare primary gastric tumor characterized by hepatocellular carcinomalike histology. HAS often causes diagnostic confusion with conventional gastric adenocarcinoma (CGA) due to the difficulty to detect hepatoid differentiation solely based on findings from hematoxylin and eosin (H&E) staining. β-catenin is highly expressed in hepatocellular carcinoma (HCC), which is involved in the maintenance of tumor initiating cells, drug resistance, tumor progression, and metastasis. Due to the scarcity of confirmed cases of HAS, there are few studies on β-catenin.
Objective: 14 patients diagnosed in our hospital were selected.
Methods: The clinical characteristics of 14 patients were statistically studied, and pathological specimens were analyzed by immunohistochemistry.
Results: We detected statistically significant difference in the expression of β-catenin (P = 0.000), glypican3 (P = 0.019), and hepar-1 (P = 0.007) between HAS cancer tissues and normal tissues. Furthermore, a significant correlation was found between the expression of β-catenin in HAS cancer tissue and normal tissue (Pearson correlation coefficient: 0.686, P = 0.007). Meanwhile, a significant correlation was observed between the expression of β-catenin and survival time (Spearman correlation coefficient= - 0.482, P = 0.003). However, we found the expression of β-catenin did not correlate with the tumor differentiation and size, age, gender, serum AFP levels, microinvasion, and metastasis (P > 0.05).
Conclusion: Our findings establish β-catenin as a useful marker that can distinguish HAS from CGA and may improve the early diagnosis to guide the appropriate and timely treatment of HAS patients.
Export Options
About this article
Cite this article as:
Aberrant β-catenin Activity in Hepatoid Adenocarcinoma of the Stomach, Current Molecular Medicine 2021; 21 (8) . https://dx.doi.org/10.2174/0929867327666200522215607
DOI https://dx.doi.org/10.2174/0929867327666200522215607 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticancer Activity of Organogallium(III) Complexes in Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Autoimmune Pancreatitis and Diagnostic Criteria
Current Immunology Reviews (Discontinued) Regional Distribution and Kinetics of Inhaled Pharmaceuticals
Current Pharmaceutical Design Implications of Nanoscale Based Drug Delivery Systems in Delivery and Targeting Tubulin Binding Agent, Noscapine in Cancer Cells
Current Drug Metabolism Malaria Chemotherapy: Recent Advances in Drug Development
Recent Patents on Anti-Infective Drug Discovery Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Janus Molecule I: Dichotomous Effects of COMT in Neuropathic vs Nociceptive Pain Modalities
CNS & Neurological Disorders - Drug Targets Discovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU
Medicinal Chemistry The Application of Phage Display in Allergy Research: Characterization of IgE, Identification of Allergens and Development of Novel Therapeutics
Current Pharmaceutical Biotechnology Biological Imaging and Spectroscopy of pH
Current Organic Chemistry Mitochondrial Serine Protease HtrA2/Omi as a Potential Therapeutic Target
Current Drug Targets Clinical Implications of COX-1 and / or COX-2 Inhibition for the Distal Gastrointestinal Tract
Current Pharmaceutical Design An Update on Hepatic Stem Cells: Bench to Bedside
Current Pharmaceutical Biotechnology Role of Graphene Nano-Composites in Cancer Therapy: Theranostic Applications, Metabolic Fate and Toxicity Issues
Current Drug Metabolism Antimetastatic Activities and Mechanisms of Bisdioxopiperazine Compounds
Anti-Cancer Agents in Medicinal Chemistry Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewing’s Sarcoma Tumor Cells
Current Pharmaceutical Biotechnology Solid Lipid Nanoparticles: A Potential Approach for Drug Delivery System
Nanoscience & Nanotechnology-Asia Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews Current Evaluation of the Millennium Phytomedicine- Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine
Current Medicinal Chemistry New Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Current Pharmaceutical Design